Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cal Cohen

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
HIV Clinical Trials|May 18, 2007
Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trialAndrew Hill, Howard Grossman, Cal Cohen, et al.
The Journal of Antimicrobial Chemotherapy|January 24, 2025
Assessing phenotypic effect of integrase strand-transfer inhibitor (INSTI)-based resistance substitutions associated with failures on cabotegravirMichelle L D'Antoni, Brie Falkard, Kristen Andreatta, et al.
The AIDS Reader|December 10, 2008
Antiretroviral treatment update from the 17th International AIDS ConferenceBrian Boyle, Cal Cohen, Edwin DeJesus, et al.
The Journal of Infectious Diseases|August 29, 2002
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategiesPablo Tebas, Keith Henry, Kristin Mondy, et al.
Viruses|December 23, 2015
Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR StudyDanielle P Porter, Martin Daeumer, Alexander Thielen, et al.
AIDS (London, England)|November 5, 2008
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimenZoe Fox, Andrew Phillips, Cal Cohen, et al.
AIDS Research and Therapy|April 8, 2025
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIVEric S Daar, Chloe Orkin, Paul E Sax, et al.
Molecules (Basel, Switzerland)|July 9, 2022
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2Joy Y Feng, Venice Du Pont, Darius Babusis, et al.
Open Forum Infectious Diseases|May 22, 2023
Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic SuppressionJose R Castillo-Mancilla, Mary Morrow, Peter W Hunt, et al.
The Journal of Infectious Diseases|May 30, 2026
Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons with HIV Starting Antiretroviral Therapy in the United States and CanadaKassem Bourgi, Aihua Bian, Lakeisha Boyd, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
HIV Clinical Trials|May 18, 2007
Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trialAndrew Hill, Howard Grossman, Cal Cohen, et al.
The Journal of Antimicrobial Chemotherapy|January 24, 2025
Assessing phenotypic effect of integrase strand-transfer inhibitor (INSTI)-based resistance substitutions associated with failures on cabotegravirMichelle L D'Antoni, Brie Falkard, Kristen Andreatta, et al.
The AIDS Reader|December 10, 2008
Antiretroviral treatment update from the 17th International AIDS ConferenceBrian Boyle, Cal Cohen, Edwin DeJesus, et al.
The Journal of Infectious Diseases|August 29, 2002
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategiesPablo Tebas, Keith Henry, Kristin Mondy, et al.
Viruses|December 23, 2015
Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR StudyDanielle P Porter, Martin Daeumer, Alexander Thielen, et al.
AIDS (London, England)|November 5, 2008
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimenZoe Fox, Andrew Phillips, Cal Cohen, et al.
AIDS Research and Therapy|April 8, 2025
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIVEric S Daar, Chloe Orkin, Paul E Sax, et al.
Molecules (Basel, Switzerland)|July 9, 2022
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2Joy Y Feng, Venice Du Pont, Darius Babusis, et al.
Open Forum Infectious Diseases|May 22, 2023
Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic SuppressionJose R Castillo-Mancilla, Mary Morrow, Peter W Hunt, et al.
The Journal of Infectious Diseases|May 30, 2026
Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons with HIV Starting Antiretroviral Therapy in the United States and CanadaKassem Bourgi, Aihua Bian, Lakeisha Boyd, et al.
Pageof 3